Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
Top Cited Papers
Open Access
- 26 April 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (8), 1350-1360
- https://doi.org/10.1002/art.41294
Abstract
Objective Assess safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). Methods A double‐blind, randomized, placebo‐controlled Phase 2 study was conducted at nine SSc clinics in the USA. Adults with dcSSc ≤ 6 years duration on stable standard‐of‐care treatment received lenabasum (N = 27) or placebo (N = 15). Lenabasum doses were 5 mg once daily (QD), 20 mg QD, or 20 mg twice daily (BID) for 4 weeks, then 20 mg BID for 8 weeks. Safety and efficacy assessments were done at weeks 4, 8, 12, and 16. Results Adverse events occurred in 63% of the lenabasum group and 60% of the placebo group, with no serious adverse events related to lenabasum. Lenabasum treatment compared to placebo was associated with greater improvement in American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score and other efficacy outcomes that assessed overall disease, skin involvement, and patient‐reported function. CRISS score increased in the lenabasum group during the study, reaching 0.33 versus 0.00 in the placebo group at Week 16 (p = 0.07, 2‐sided mixed model repeated measures). Gene expression in inflammation and fibrosis pathways was reduced and inflammation and fibrosis improved by histological evaluation of skin biopsies from the lenabasum group compared to the placebo group (all p ≤ 0.05). Conclusion Despite a short trial duration in a small number of patients, lenabasum improved efficacy outcomes and underlying disease pathology with a favorable safety profile in this Phase 2 study in dcSSc.This publication has 49 references indexed in Scilit:
- The Cannabinoid Receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic interventionPharmacological Research, 2012
- g:Profiler—a web server for functional interpretation of gene lists (2011 update)Nucleic Acids Research, 2011
- Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic SclerosisThe American Journal of Pathology, 2010
- The 5-D itch scale: a new measure of pruritusBritish Journal of Dermatology, 2009
- Innate immunity and inflammation in systemic sclerosisCurrent Opinion in Rheumatology, 2009
- Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblastsRheumatology, 2009
- The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion‐induced cardiomyopathyThe FASEB Journal, 2009
- Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cannabinoid signallingLife Sciences, 2006
- Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosisArthritis & Rheumatism, 1999